Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Mar 29, 2024

Anti-Alpha-synuclein (phospho S129) antibody

RRID:AB_2728613
Type: Antibody

Proper Citation

(Abcam Cat# ab168381, RRID:AB_2728613)

Antibody Information

URL: http://antibodyregistry.org/AB_2728613

Proper Citation: (Abcam Cat# ab168381, RRID:AB_2728613)

Target Antigen: alpha Synuclein phosphorylated on Ser129

Host Organism: rabbit

Clonality: monoclonal

Comments: Suitable for: WB

Antibody Name: Anti-Alpha-synuclein (phospho S129) antibody

Description: This monoclonal targets alpha Synuclein phosphorylated on Ser129

Target Organism: human

Clone ID: MJF-R13 (8-8)

Antibody ID: AB_2728613

Vendor: Abcam

Catalog Number: ab168381

Ratings and Alerts

No rating or validation information has been found for Anti-Alpha-synuclein (phospho S129) antibody.

No alerts have been found for Anti-Alpha-synuclein (phospho S129) antibody.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Izco M, et al. (2021) Glial activation precedes alpha-synuclein pathology in a mouse model of Parkinson's disease. Neuroscience research, 170, 330.

Kim K, et al. (2021) TRIP12 ubiquitination of glucocerebrosidase contributes to neurodegeneration in Parkinson's disease. Neuron, 109(23), 3758.

Henderson MX, et al. (2020) Glucocerebrosidase Activity Modulates Neuronal Susceptibility to Pathological ?-Synuclein Insult. Neuron, 105(5), 822.

Bassil F, et al. (2020) Amyloid-Beta (A?) Plaques Promote Seeding and Spreading of Alpha-Synuclein and Tau in a Mouse Model of Lewy Body Disorders with A? Pathology. Neuron, 105(2), 260.

Zhu G, et al. (2020) TRIM11 Prevents and Reverses Protein Aggregation and Rescues a Mouse Model of Parkinson's Disease. Cell reports, 33(9), 108418.

Fanning S, et al. (2019) Lipidomic Analysis of ?-Synuclein Neurotoxicity Identifies Stearoyl CoA Desaturase as a Target for Parkinson Treatment. Molecular cell, 73(5), 1001.

Kim S, et al. (2019) Transneuronal Propagation of Pathologic ?-Synuclein from the Gut to the Brain Models Parkinson's Disease. Neuron, 103(4), 627.

Delic V, et al. (2018) Sensitivity and specificity of phospho-Ser129 ?-synuclein monoclonal antibodies. The Journal of comparative neurology, 526(12), 1978.

Henderson MX, et al. (2018) LRRK2 activity does not dramatically alter ?-synuclein pathology in primary neurons. Acta neuropathologica communications, 6(1), 45.